Form 4: Halozyme Therapeutics SVP, Chief Technical Officer, Michael J. LaBarre, Reports Acquisition of Stock Options and Restricted Stock Units
SEC Form 4 Filing
Michael J. LaBarre, SVP, Chief Technical Officer of Halozyme Therapeutics, reports the acquisition of stock options and restricted stock units.
Summary
- On February 23, 2024, Michael J. LaBarre, SVP, Chief Technical Officer of Halozyme Therapeutics, acquired 19,674 options to purchase common stock at an exercise price of $40.56, vesting over time.
- LaBarre also acquired 18,985 restricted stock units (RSUs) which vest one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter.
- Following these transactions, LaBarre directly owns 19,674 derivative securities and 18,985 restricted stock units.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. Insider ownership is generally viewed favorably, but the specific impact depends on the individual's trading history and the overall context.
Positives
- The acquisition of stock options and restricted stock units by a high-ranking officer signals confidence in the company's future performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Stakeholder Impact
- The acquisition of stock options and restricted stock units by a company officer can positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 02/23/2024 | Date of transaction: Acquisition of stock options and restricted stock units. |
| 02/23/2025 | First vesting date for both stock options and restricted stock units. |
| 02/27/2024 | Date of Form 4 filing. |
| 02/23/2034 | Expiration date for the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.